Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14856022 | 1.00 | RAB9A (0.62) | RAB9ANPC1HPGDCYP1A2CYP2C19 | |
| SCHEMBL8313089 | 0.87 | NPC1 (0.46) | RAB9ANPC1HPGDCYP1A2CYP2C19 | |
| SCHEMBL14856486 | 0.86 | POLB (0.50) | RAB9ANPC1HPGDCYP1A2CYP2C19 | |
| SCHEMBL14856186 | 0.86 | POLB (0.50) | RAB9ANPC1HPGDCYP1A2CYP2C19 | |
| SCHEMBL8313720 | 0.86 | NPC1 (0.52) | RAB9ANPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL9200588 | 0.86 | NPC1 (0.52) | RAB9ANPC1HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL8311826 | 0.85 | NPC1 (0.68) | RAB9ANPC1HPGDCYP1A2CYP2C19 | |
| SCHEMBL8315644 | 0.84 | HDAC4 (0.47) | RAB9ANPC1HPGDCYP1A2CYP2C19 | |
| SCHEMBL8313869 | 0.81 | RAB9A (0.42) | RAB9ANPC1HPGDCYP1A2CYP2C19 | |
| SCHEMBL8311437 | 0.81 | KMT2A (0.52) | OPRK1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-07-04 | — | — | US | claimed |
| EP-2580196-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Ltd. (GB) | 2013-04-17 | — | — | EP | claimed |
| WO-2011154696-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | claimed |
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-07-04 | — | — | US | disclosed |
| EP-2580196-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154696-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
| EP-0351856-B1 | Thiazolo[5,4-b]azepine compounds | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-09-15 | — | — | EP | disclosed |
| US-5300639-A | 2-oxo-3-carbonylamino-substituted azepine intermediates; lipoperoxide formation inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-05 | — | — | US | disclosed |
| US-5118806-A | Enzyme inhibitor for lipoxygenase; useful for treating cancer, hepatic diseases, inflammation, cerebrovascular diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-06-02 | — | — | US | disclosed |
| US-4956360-A | LIPOPEROXIDE INHIBITORS, ENZYME INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-11 | — | — | US | disclosed |
| EP-0351856-A2 | Thiazolo[5,4-b]azepine compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | IL6, TNF, IL1B | RAB9A 3124/4885NPC1 2952/4885HPGD 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.